tagraxofusp-based therapy to eradicate mrd in patients with aml prior to allohct
Published 1 year ago • 85 plays • Length 1:59Download video MP4
Download video MP3
Similar videos
-
1:15
managing patients with transplant-ineligible bdpcn with tagraxofusp
-
1:46
tagraxofusp combined with azacitidine and venetoclax in the treatment of bpdcn and aml
-
1:17
insights into a study evaluating tagraxofusp for the treatment of bpdcn
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
33:18
transfusion therapy
-
2:41
advances in the treatment and prognosis of ttp
-
5:43
antigen type | transfusion medicine
-
2:11
beat aml master trial: novel precision medicine approach in aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
2:42
the use of targeted therapy to prevent relapse post-transplant
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:57
insights into the treatment of patients with flt3-mutated aml & the role of maintenance therapy
-
1:49
bringing precision medicine and mrd into clinical strategies
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
2:17
tagraxofusp for r/r myelofibrosis shows promise
-
2:43
gemtuzumab ozogamicin in frontline aml therapy
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
2:20
best treatment strategy for flt3 itd aml
-
8:40
investigating pp2a-based therapeutic strategies for kmt2a-rearranged acute leukemia
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
6:44
the current landscape for the treatment of r/r aml in the post-transplant setting